Abstract
While outcome for pediatric T lymphoblastic lymphoma (T-LBL) has improved with Acute Leukemia-type therapy, survival after relapse remains rare. Few prognostic markers have been identified and the value of Minimal Residual Disease (MRD) is less clear than in T-ALL. Mutations of NOTCH1 and/or FBXW7 (N/F) identify good prognosis T-LBL and both MRD and high-level Minimal Disseminated Disease (MDD) are reported to be of poor prognosis. We evaluated MDD status by 8-color flow cytometry (MFC) and/or digital droplet PCR (ddPCR) in 86 French pediatric T-LBL, of which N/F status was known for 65 (61 treated on the Euro-LB02 protocol). Both techniques gave identical results for MDD/MRD values above 0.1%, allowing compilation. While an MDD threshold of 1% had no prognostic significance, the 54% (44/82) of protocol-treated patients with MDD ≥0.1% had a relatively favorable outcome (overall survival/OS; p = 0.026). MDD 0.1% status had no prognostic significance in the 68% of patients with N/F mutations, whereas low/negative MDD status (9/61) identified N/F germline patients at a high risk of relapse (5-year OS of 44.4% vs 90% for MDD ≥ 0.1%,p = 0.014; and a 5-year DFS of 50% vs 90.9% respectively, p = 0.041). Combining oncogenetic and MDD status allows identification of 85% of patients with an excellent outcome (5-year OS 91.9% and DFS 95%) and 15% of N/F germline/MDD< 0.1% patients who clearly require early alternative treatment (5-year OS 44.4%; p< 0.0001 and DFS 50%; p = 0.0001).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT00275106
Funding Statement
This study was supported by: The Necker LBL RELYE (Reseau des lymphomes de l Enfant) tissue bank is supported by IMAGINE for Margo via the SFCE, the Institut National du Cancer and the CARPEM SIRIC. Research support was provided by the League National de Recherche sur le Cancer (Enfants, Adolescents et Cancer), by Enfants et Sante and by the SFCE. The Trousseau team was supported by the Recherche en Hemopathies Malignes de l Enfant (RHME).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The EURO-LB02 protocol was a randomized controlled study, derived from the Berlin-Frankfurt-Munich BFM90 protocol but without prophylactic central nervous system irradiation, involving patients aged <22y with de-novo LBL in 8 European cooperative groups (NCT00275106). The study was interrupted prematurely due to excessive toxicity, but the prednisone arm was continued in France, with central registration of clinical data in Lyon. From 2008 onwards, prospective flow cytometry was performed centrally (Lyon) for the French cohort. Between December 2004 and December 2017, 299 patients with T-LBL were enrolled in 30 institutions of the Societe Francaise de lutte contre les Cancers et leucemies de l Enfant et de l adolescent (SFCE). As per the declaration of Helsinki, the Lyon ethics committee approved the study and signed informed consent was obtained for all patients.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
-Central registration of clinical data in Lyon for the French cohort. -Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma (PMID 28983060)
